2026 Volume 41 Issue 1 Pages 74-79
PHESGOⓇ combination for subcutaneous injection MA/IN (PHESGOⓇ) is a combination of pertuzumab and trastuzumab with hyaluronidase for anti-cancer drug. PHESGOⓇ obtained marketing approval in Japan in September 2023 and is launched in the Japanese market in November 2023. Their combination is widely recommended worldwide and has been established as a standard of care for HER2-positive breast cancer. However, improvement is required because of the prolonged time of intravenous infusion. PHESGO contains hyaluronidase, it allows for the administration of drugs that cannot be administered with subcutaneous formulations. It is expected to simplify administration and shorten time. This paper introduces the development process, characteristics of this drug, and clinical trial results.
